Family-focused behavioural support still improves HbA1c in youth

Design

Updated systematic review and meta-analysis of 46 randomised trials

Population

Youth and young adults up to age 25 with type 1 diabetes

Primary outcome

Change in HbA1c with adherence-promoting behavioural interventions

Effect

Overall effect size 0.12; family-focused 0.29 vs youth 0.05 and parent 0.04

Diabetes technology has advanced enormously, raising the question of whether behavioural support still adds anything for young people with type 1 diabetes. This updated meta-analysis of 46 randomised trials says it does, modestly, and shows which approaches work.

Across trials, adherence-promoting behavioural interventions produced a small overall improvement in HbA1c (standardised effect size 0.12). The more informative finding is the pattern: multicomponent interventions outperformed single-component ones, and family-focused approaches (effect size 0.29) clearly beat youth-focused (0.05) or parent-focused (0.04) strategies. Pilot trials overstated the effect compared with full trials.

The practical change is in targeting. Behavioural support should not be dropped in the technology era, but it should be built around the family rather than the young person or parent alone. A modest average effect still matters at the population level, and the family-focused design is what makes it worthwhile.

• Updated meta-analysis of 46 randomised trials of behavioural interventions in youth with type 1 diabetes.
• Overall HbA1c benefit was small (standardised effect size 0.12).
• Family-focused interventions (effect size 0.29) beat youth- (0.05) or parent-focused (0.04) ones.
• Multicomponent interventions outperformed single-component ones.
• Pilot trials overstated effects relative to full trials.

Why it matters

It answers whether behavioural support is still worth it in the technology era, and points to family-focused design as the deciding factor.

Don't overread it

The average effect is small, and the larger family-focused estimate still represents a modest HbA1c change, not a substitute for sound medical and technological management.

The statistics, in plain English

A standardised effect size of 0.12 is small; 0.29 for family-focused work is small-to-moderate. The gap between pilot (0.36) and full trials (0.07) is a reminder that early promising results often shrink when tested rigorously.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.